Metabolomics in Pulmonary Diseases

Dear Colleagues,

Metabolomics, the comprehensive analysis of small molecules in biological samples, has emerged as a powerful tool in the field of pulmonary medicine such as chronic obstructive pulmonary disease (COPD), asthma, pulmonary fibrosis, Sarcoidosis, lung cancer, and viral and bacterial pneumonia. Pulmonary diseases encompass a wide range of conditions that are characterized by complex pathophysiological processes involving inflammation, oxidative stress, tissue remodeling, and metabolic dysregulation. One of the key rationales for utilizing metabolomics in pulmonary diseases is the ability to capture the dynamic metabolic changes occurring in the lungs and systemic circulation. Metabolites represent the end products of cellular metabolism and reflect the functional state of cells and tissues. By analyzing the global metabolic profile, metabolomics can provide a snapshot of the metabolite alterations associated with pulmonary diseases that can unravel dysregulated metabolic pathways in different lung conditions. This holistic approach allows for the identification of novel biomarkers for early diagnosis, disease classification, and insights into the molecular processes driving disease progression. Using metabolomics, the accurate clustering of pulmonary diseases can facilitate personalized medicine approaches that may hold great promise for improving treatment outcomes, minimizing side effects, and enhancing patient care in pulmonary disease. The scope of this Special Issue includes preclinical and clinical research in the field of metabolomics in pulmonary diseases. The Special Issue welcomes original articles, reviews, and perspectives that contribute to understanding metabolic alterations, diagnostics and prognostics biomarker discovery and stratification of diseases. We encourage submissions of papers using various metabolomics platforms including mass spectrometry, nuclear magnetic resonance and other analytical techniques on human clinical samples, animal models, and cell cultures. This Special Issue aims to provide an opportunity for researchers and experts in the field to share their new findings, methods and ideas about metabolomics and lung diseases.

Dr. Mohammad Mehdi Banoei
Dr. Mehdi Mirsaeidi
Guest Editors

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Metabolites is an international peer-reviewed open access monthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2700 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

• metabolomics
• diagnostic and prognostic biomarkers
• pathogenesis
• inflammation
• progression of disease